IKKβ activation is sufficient for RANK-independent osteoclast differentiation and osteolysis

Journal of Bone and Mineral Research

Volumn 25, Issue 6, 2010, Pages 1282-1294

  Otero, Jesse E ^a   Dai, Simon ^a   Alhawagri, Muhammad A ^a   Darwech, Isra ^a   Abu Amer, Yousef ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IKK ; NF B; Osteoclast; Osteolysis; Rank

Indexed keywords

I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; CHUK PROTEIN, MOUSE; I KAPPA B KINASE; IKBKB PROTEIN, MOUSE; NEMO PROTEIN, MOUSE; OSTEOCLAST DIFFERENTIATION FACTOR; SIGNAL PEPTIDE;

ADENOVIRUS; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CALVARIA; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE TRANSFER; HUMAN; KNEE; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; SIGNAL TRANSDUCTION; ANIMAL; BONE DEVELOPMENT; CYTOLOGY; ENZYMOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHENOTYPE; PROTEIN BINDING;

ANIMALS; CELL DIFFERENTIATION; ENZYME ACTIVATION; I-KAPPA B KINASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MONOCYTES; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; PHENOTYPE; PROTEIN BINDING; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 77953527361     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.4     Document Type: Article

References (44)

1. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Amer J Pathol. 2007;170:427-435.
2. Abu-Amer Y. Advances in osteoclast differentiation and function. Current drug targets. Immune, endo and metab dis. 2005;5:347-355.
3. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4:638-649.
4. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med (Berlin, Germany). 2005;83:170-179.
5. Destaing O, Sanjay A, Itzstein C, et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol Biol Cell. 2008;19:394-404.
6. 3-integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000;105:433-440.
7. 3-integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007;176:877-888.
8. Zou W, Reeve JL, Liu Y, Teitelbaum SL, Ross FP. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. Mol cell. 2008;31:422-431.
9. Wang Y, Lebowitz D, Sun C, Thang H, Grynpas MD, Glogauer M. Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis. J Bone Min Res. 2008;23:260-270.
10. Teitelbaum SL. Bone resorption by osteoclasts. Science (New York). 2000;289:1504-1508.
11. Iotsova V, Caamaäno J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med. 1997;3:1285-1289.
12. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R, Novack DV. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest. 2008;118:2088-2097.
13. Vaira S, Johnson T, Hirbe AC, et al. RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA. 2008;105:3897-3902.
14. Rothwarf DM, Karin M. The NF-κB activation pathway: a paradigm in information transfer from membrane to nucleus. Science's STKE. 1999;1999:RE1.
15. Hèacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Science's STKE. 2006;2006:re13.
16. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature. 2000;403:103-118.
17. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem. 2004;279:37219-37222.
18. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004;10:617-624.
19. Chaisson ML, Branstetter DG, Derry JM, et al. Osteoclast differentiation is impaired in the absence of IκB kinase-α. J Biol Chem. 2004;279:54841-54848.
20. Ruocco MG, Maeda S, Park JM, et al. IκB kinase-β, but not IκK-α, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 2005;201:1677-1687.
21. Otero JE, Dai S, Foglia D, et al. Defective osteoclastogenesis by IKKβ null precursors is a result of receptor activator of NF-κB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J Biol Chem. 2008;283:24546-24553.
22. Chiu WS, McManus JF, Notini AJ, Cassady AI, Zajac JD, Davey RA. Transgenic mice that express Cre recombinase in osteoclasts. Genesis (New York, N.Y.: 2000). 2004;39:178-185.
23. Pasparakis M, Courtois G, Hafner M, et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature. 2002;417:861-866.
24. Chaisson ML, Branstetter DG, Derry JM, et al. Osteoclast differentiation is impaired in the absence of IkB kinase-α. J Biol Chem. 2004;279:54841-54848.
25. Vaira S, Johnson T, Hirbe AC, et al. RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci (USA). 2008;105:3897-3902.
26. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci (USA). 1999;96:3540-3545.
27. Yamashita T, Yao Z, Li F, et al. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007;282:18245-18253.
28. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science (New York, N.Y.). 1997;278:860-866.
29. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science (New York, N.Y.). 1999;284:309-313.
30. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene therapy. 2000;7:1063-1066.
31. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL. A simple method for the rapid generation of recombinant adenovirus vectors. Gene therapy. 2000;7:1034-1038.
32. Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science (New York, N.Y.). 1994;266:443-448.
33. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95:13453-13458.
34. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050-5055.
35. Rudolph D, Yeh WC, Wakeham A, et al. Severe liver degeneration and lack of NF-κB activation in NEMO/IKKgamma-deficient mice. Genes & development. 2000;14:854-862.
36. May MJ, Marienfeld RB, Ghosh S. Characterization of the IκB-kinase NEMO binding domain. J Biol Chem. 2002;277:45992-46000.
37. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995;9:576-596.
38. Senftleben U, Cao Y, Xiao G, et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science. 2001;293:1495-1499.
39. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3:889-901.
40. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004; 25:280-288.
41. Lam J, Abu-Amer Y, Nelson C, Fermont D, Ross F, Teitelbaum S. Tumor necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheu Dis. 2002;61:82-83.
42. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115:282-290.
43. Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005;202:589-595.
44. Simsek S, Basoski NM, Bravenboer N, et al. Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-κB, osteoprotegerin, or sequestosome-1 gene defects. J Clin Endo Metab. 2007;92:1897-1901.